M&A Deal Summary

Sanofi Acquires Genzyme

On February 16, 2011, Sanofi acquired life science company Genzyme for 20.1B USD

Acquisition Highlights
  • This is Sanofi’s 7th transaction in the Life Science sector.
  • This is Sanofi’s largest (disclosed) transaction.
  • This is Sanofi’s 7th transaction in the United States.
  • This is Sanofi’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2011-02-16
Target Genzyme
Sector Life Science
Buyer(s) Sanofi
Deal Type Add-on Acquisition
Deal Value 20.1B USD
Advisor(s) Credit Suisse Investment Banking
Goldman Sachs (Financial)
Ropes & Gray (Legal)

Target

Genzyme

Cambridge, Massachusetts, United States
Genzyme laboratory in Framingham, Massachusetts.
Genzyme laboratory in Framingham, Massachusetts.
Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.

Search 200,388 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sanofi

Paris, France
Category Company
Founded 1994
Sector Life Science
Employees86,088
Revenue 46.4B EUR (2023)
DESCRIPTION

Sanofi is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi was founded in 1994 and is based in Paris, France.

DEAL STATS #
Overall 14 of 27
Sector (Life Science) 7 of 18
Type (Add-on Acquisition) 10 of 21
State (Massachusetts) 1 of 4
Country (United States) 7 of 16
Year (2011) 1 of 2
Size (of disclosed) 1 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-09-27 VaxDesign

Orlando, Florida, United States

VaxDesign is a privately held U.S. biotechnology company, based in Orlando, Florida, that develops, manufactures and markets in vitro models of the human immune system. VaxDesign is the developer of the Modular IMmune In-vitro Construct (MIMIC®) technology that meldsimmunology with engineering to find solutions to complex biological problems.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-07-11 Dermik Laboratories

Bridgewater, New Jersey, United States

Dermik Laboratories, Inc. portfolio includes major therapeutic and aesthetic dermatology brands such as Benzaclin® for the treatment of acne, Carac® for the treatment of keratoses and Sculptra®, a facial injectable for the correction of facial wrinkles and folds.

Sell $425M
Mergr

Product

Company

Legal